<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Merck & Company, Inc. — News on 6ix</title>
<link>https://6ix.com/company/merck-and-company-inc</link>
<description>Latest news and press releases for Merck & Company, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 12 May 2026 10:45:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/merck-and-company-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68359d1a78dffbe2df107715.webp</url>
<title>Merck & Company, Inc.</title>
<link>https://6ix.com/company/merck-and-company-inc</link>
</image>
<item>
<title>Merck Highlights New Long-Term Data and Advancements Across Broad Oncology Portfolio and Pipeline Research at ASCO 2026</title>
<link>https://6ix.com/company/merck-and-company-inc/news/merck-highlights-new-long-term-data-and-advancements-across-broad-oncology-portfolio-and-pipeline-research-at-asco-2026</link>
<guid isPermaLink="true">https://6ix.com/company/merck-and-company-inc/news/merck-highlights-new-long-term-data-and-advancements-across-broad-oncology-portfolio-and-pipeline-research-at-asco-2026</guid>
<pubDate>Tue, 12 May 2026 10:45:00 GMT</pubDate>
<description>RAHWAY, N.J., May 12, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new research from more than 100 abstracts across over 25 types of cancer from the company’s comprehensive oncology portfolio and pipeline will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29-June 2). The data reinforce the long-term impact of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, and Merck’s rapidly advancing pipeline ac</description>
</item>
<item>
<title>Merck Scientists Publish Landmark Paper on Novel Method for Large-Scale Biocatalytic Synthesis of Investigational Oral PCSK9 Inhibitor, Enlicitide Decanoate</title>
<link>https://6ix.com/company/merck-and-company-inc/news/merck-scientists-publish-landmark-paper-on-novel-method-for-large-scale-biocatalytic-synthesis-of-investigational-oral-pcsk9-inhibitor-enlicitide-decanoate</link>
<guid isPermaLink="true">https://6ix.com/company/merck-and-company-inc/news/merck-scientists-publish-landmark-paper-on-novel-method-for-large-scale-biocatalytic-synthesis-of-investigational-oral-pcsk9-inhibitor-enlicitide-decanoate</guid>
<pubDate>Thu, 07 May 2026 18:05:00 GMT</pubDate>
<description>RAHWAY, N.J., May 07, 2026--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today the publication of work describing the large-scale synthesis of enlicitide decanoate, the company’s investigational oral PCSK9 inhibitor, using a tailored suite of enzymes in the latest issue of the peer reviewed journal Science.</description>
</item>
<item>
<title>PedvaxHIB (Merck) Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035F</title>
<link>https://6ix.com/company/merck-and-company-inc/news/pedvaxhib-merck-market-research-report-2026-epidemiology-pipeline-analysis-market-insights-and-forecasts-2020-2025-2025-2030f-2035f</link>
<guid isPermaLink="true">https://6ix.com/company/merck-and-company-inc/news/pedvaxhib-merck-market-research-report-2026-epidemiology-pipeline-analysis-market-insights-and-forecasts-2020-2025-2025-2030f-2035f</guid>
<pubDate>Thu, 07 May 2026 15:07:00 GMT</pubDate>
<description>Key opportunities in the market include expanding global immunization programs, enhancing public-private partnerships, and increasing preventive healthcare investments. Emphasizing routine childhood immunization and optimizing cold-chain logistics will further drive market growth. Focused strategies for specific populations offer growth potential.Dublin, May 07, 2026 (GLOBE NEWSWIRE) -- The "PedvaxHIB Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been adde</description>
</item>
<item>
<title>Pergonal (Merck) Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035F</title>
<link>https://6ix.com/company/merck-and-company-inc/news/pergonal-merck-market-research-report-2026-epidemiology-pipeline-analysis-market-insights-and-forecasts-2020-2025-2025-2030f-2035f</link>
<guid isPermaLink="true">https://6ix.com/company/merck-and-company-inc/news/pergonal-merck-market-research-report-2026-epidemiology-pipeline-analysis-market-insights-and-forecasts-2020-2025-2025-2030f-2035f</guid>
<pubDate>Thu, 07 May 2026 15:02:00 GMT</pubDate>
<description>Key market opportunities include growing infertility rates, increased IVF adoption, and rising healthcare expenditure. Demand for Pergonal will surge due to personalized hormone treatments and expanded access in emerging markets. Despite tariff challenges, regional manufacturing investments may offset costs.Dublin, May 07, 2026 (GLOBE NEWSWIRE) -- The "Pergonal Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering. T</description>
</item>
<item>
<title>Pergoveris (Merck) Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035F</title>
<link>https://6ix.com/company/merck-and-company-inc/news/pergoveris-merck-market-research-report-2026-epidemiology-pipeline-analysis-market-insights-and-forecasts-2020-2025-2025-2030f-2035f</link>
<guid isPermaLink="true">https://6ix.com/company/merck-and-company-inc/news/pergoveris-merck-market-research-report-2026-epidemiology-pipeline-analysis-market-insights-and-forecasts-2020-2025-2025-2030f-2035f</guid>
<pubDate>Thu, 07 May 2026 14:51:00 GMT</pubDate>
<description>Key market opportunities for the Pergoveris market include increased adoption of IVF procedures and precision hormone therapies, expanded fertility tourism, and rising infertility awareness. Advances in recombinant hormone technologies and patient-friendly injectable formats further drive growth, particularly amid tariff impacts encouraging domestic biologic production.Dublin, May 07, 2026 (GLOBE NEWSWIRE) -- The "Pergoveris Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights &</description>
</item>
<item>
<title>Merck Animal Health Selects Salesforce’s Agentforce Life Sciences for Customer Engagement to Transform Animal Care and Enhance Support Experiences for Employees</title>
<link>https://6ix.com/company/merck-and-company-inc/news/merck-animal-health-selects-salesforces-agentforce-life-sciences-for-customer-engagement-to-transform-animal-care-and-enhance-support-experiences-for-employees</link>
<guid isPermaLink="true">https://6ix.com/company/merck-and-company-inc/news/merck-animal-health-selects-salesforces-agentforce-life-sciences-for-customer-engagement-to-transform-animal-care-and-enhance-support-experiences-for-employees</guid>
<pubDate>Wed, 06 May 2026 13:00:00 GMT</pubDate>
<description>SAN FRANCISCO & RAHWAY, N.J., May 06, 2026--Salesforce (NYSE: CRM), the world’s #1 AI CRM, and Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc. (NYSE: MRK), today announced that Merck Animal Health has selected Agentforce Life Sciences for Customer Engagement to create a unified, 360-degree view and support experience for veterinarians, pet owners, and production animal farmers across all channels.</description>
</item>
<item>
<title>Merck Completes Acquisition of Terns Pharmaceuticals, Inc.</title>
<link>https://6ix.com/company/merck-and-company-inc/news/merck-completes-acquisition-of-terns-pharmaceuticals-inc</link>
<guid isPermaLink="true">https://6ix.com/company/merck-and-company-inc/news/merck-completes-acquisition-of-terns-pharmaceuticals-inc</guid>
<pubDate>Tue, 05 May 2026 12:45:00 GMT</pubDate>
<description>RAHWAY, N.J., May 05, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the successful completion of the acquisition of Terns Pharmaceuticals, Inc. ("Terns") (Nasdaq: TERN).</description>
</item>
<item>
<title>Merck & Co., Inc., Rahway, N.J., USA Announces First-Quarter 2026 Financial Results; Highlights Significant Regulatory Approvals and Clinical Milestones</title>
<link>https://6ix.com/company/merck-and-company-inc/news/merck-and-co-inc-rahway-nj-usa-announces-first-quarter-2026-financial-results-highlights-significant-regulatory-approvals-and-clinical-milestones</link>
<guid isPermaLink="true">https://6ix.com/company/merck-and-company-inc/news/merck-and-co-inc-rahway-nj-usa-announces-first-quarter-2026-financial-results-highlights-significant-regulatory-approvals-and-clinical-milestones</guid>
<pubDate>Thu, 30 Apr 2026 10:30:00 GMT</pubDate>
<description>RAHWAY, N.J., April 30, 2026--Merck & Co., Inc., Rahway, N.J., USA Announces First-Quarter 2026 Financial Results</description>
</item>
<item>
<title>Merck’s Playing with Heart Program Teams Up With Professional Baseball Clubs and Baseball Legends to Help Raise Awareness About LDL-C, Called "Bad" Cholesterol, and How It May Impact the Risk of Heart Attack or Stroke</title>
<link>https://6ix.com/company/merck-and-company-inc/news/mercks-playing-with-heart-program-teams-up-with-professional-baseball-clubs-and-baseball-legends-to-help-raise-awareness-about-ldl-c-called-bad-cholesterol-and-how-it-may-impact-the-risk-of-heart-attack-or-stroke</link>
<guid isPermaLink="true">https://6ix.com/company/merck-and-company-inc/news/mercks-playing-with-heart-program-teams-up-with-professional-baseball-clubs-and-baseball-legends-to-help-raise-awareness-about-ldl-c-called-bad-cholesterol-and-how-it-may-impact-the-risk-of-heart-attack-or-stroke</guid>
<pubDate>Tue, 28 Apr 2026 10:45:00 GMT</pubDate>
<description>RAHWAY, N.J., April 28, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced a collaboration with nine professional baseball teams and former professional baseball players to launch the Playing with Heart educational program to help educate adults about the importance of knowing their low-density lipoprotein cholesterol (LDL-C), called "bad" cholesterol, number and the potential increased risk of heart attack or stroke.</description>
</item>
<item>
<title>Gastroesophageal Adenocarcinoma Market Research Report 2026, Competitive Analysis of ALX Oncology, Merck, AstraZeneca, BeOne Medicines, Taiho Pharmaceuticals, Eli Lilly - Global Forecast to 2035</title>
<link>https://6ix.com/company/merck-and-company-inc/news/gastroesophageal-adenocarcinoma-market-research-report-2026-competitive-analysis-of-alx-oncology-merck-astrazeneca-beone-medicines-taiho-pharmaceuticals-eli-lilly-global-forecast-to-2035</link>
<guid isPermaLink="true">https://6ix.com/company/merck-and-company-inc/news/gastroesophageal-adenocarcinoma-market-research-report-2026-competitive-analysis-of-alx-oncology-merck-astrazeneca-beone-medicines-taiho-pharmaceuticals-eli-lilly-global-forecast-to-2035</guid>
<pubDate>Tue, 28 Apr 2026 08:02:00 GMT</pubDate>
<description>Gastroesophageal adenocarcinoma (GEA), a cancer prevalent in the esophagus' glandular cells or stomach's gastroesophageal junction, is on the rise due to risk factors like GERD, obesity, and smoking. This aggressive cancer is often diagnosed at advanced stages, complicating treatment and worsening prognosis. Market growth is driven by the aging population and lifestyle-related risks, boosting demand for diagnostics and therapies. Leading companies like Merck and AstraZeneca are advancing GEA tre</description>
</item>
<item>
<title>Peripheral T-Cell Lymphoma Market to Witness Significant Expansion at a CAGR of 7% During the Forecast Period (2026–2036) Amid Advancing Treatment Landscape | DelveInsight</title>
<link>https://6ix.com/company/merck-and-company-inc/news/peripheral-t-cell-lymphoma-market-to-witness-significant-expansion-at-a-cagr-of-7percent-during-the-forecast-period-2026-2036-amid-advancing-treatment-landscape-or-delveinsight</link>
<guid isPermaLink="true">https://6ix.com/company/merck-and-company-inc/news/peripheral-t-cell-lymphoma-market-to-witness-significant-expansion-at-a-cagr-of-7percent-during-the-forecast-period-2026-2036-amid-advancing-treatment-landscape-or-delveinsight</guid>
<pubDate>Mon, 27 Apr 2026 17:00:00 GMT</pubDate>
<description>The peripheral T-cell lymphoma treatment market is witnessing steady growth, primarily driven by the increasing incidence, leading to an increased patient population, which fuels the ongoing treatment demand. Additionally, the launch of emerging therapies such as Duvelisib (COPIKTRA) (Secura Bio), Lacutamab (IPH4102) (Innate Pharma), Linperlisib (YY-20394/linprixetine) (Shanghai YingLi Pharmaceutical), KEYTRUDA (Merck), OPDIVO (BMS), Golidocitinib (AZD4205/DZD4205) (Dizal Pharmaceuticals), and o</description>
</item>
<item>
<title>Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.</title>
<link>https://6ix.com/company/merck-and-company-inc/news/merck-announces-expiration-of-hart-scott-rodino-act-waiting-period-to-acquire-terns-pharmaceuticals-inc</link>
<guid isPermaLink="true">https://6ix.com/company/merck-and-company-inc/news/merck-announces-expiration-of-hart-scott-rodino-act-waiting-period-to-acquire-terns-pharmaceuticals-inc</guid>
<pubDate>Fri, 24 Apr 2026 10:45:00 GMT</pubDate>
<description>RAHWAY, N.J., April 24, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), in connection with Merck’s pending acquisition of Terns Pharmaceuticals, Inc. ("Terns") (Nasdaq: TERN) expired at 11:59 p.m., Eastern Time, on April 23, 2026.</description>
</item>
<item>
<title>Survey Shows More Than 3 in 5 Americans Use AI Tools for Medical Information, but Most Take Steps to Check Sources and Information</title>
<link>https://6ix.com/company/merck-and-company-inc/news/survey-shows-more-than-3-in-5-americans-use-ai-tools-for-medical-information-but-most-take-steps-to-check-sources-and-information</link>
<guid isPermaLink="true">https://6ix.com/company/merck-and-company-inc/news/survey-shows-more-than-3-in-5-americans-use-ai-tools-for-medical-information-but-most-take-steps-to-check-sources-and-information</guid>
<pubDate>Thu, 23 Apr 2026 13:00:00 GMT</pubDate>
<description>Many Americans are turning to AI tools for medical information, but there are conflicting views about the trustworthiness of the results. More than three in five (62%) of Americans have used AI tools like medical chatbots, ChatGPT, Google Assistant, Siri, Google Gemini for medical information, according to a recent poll conducted online by The Harris Poll on behalf of Merck Manuals among 2,057 U.S. adults. About a third of Americans (32%) say they do not trust the medical information provided by</description>
</item>
<item>
<title>Merck and Google Cloud Partner to Accelerate Agentic AI Enterprise Transformation</title>
<link>https://6ix.com/company/merck-and-company-inc/news/merck-and-google-cloud-partner-to-accelerate-agentic-ai-enterprise-transformation</link>
<guid isPermaLink="true">https://6ix.com/company/merck-and-company-inc/news/merck-and-google-cloud-partner-to-accelerate-agentic-ai-enterprise-transformation</guid>
<pubDate>Wed, 22 Apr 2026 12:00:00 GMT</pubDate>
<description>Cloud Next '26 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Google Cloud today announced a landmark partnership to enhance Merck's digital backbone as an AI-enabled enterprise. This multi-year investment, valued at up to $1 billion, will deploy an agentic platform across Merck's research & development (R&D), manufacturing, commercial, and corporate functions—and includes Google Cloud engineers working alongside Merck teams to deploy Google Cloud's most sophisti</description>
</item>
<item>
<title>FDA Approves Merck’s Once-Daily IDVYNSO™ (doravirine/islatravir)</title>
<link>https://6ix.com/company/merck-and-company-inc/news/fda-approves-mercks-once-daily-idvynsotm-doravirineislatravir</link>
<guid isPermaLink="true">https://6ix.com/company/merck-and-company-inc/news/fda-approves-mercks-once-daily-idvynsotm-doravirineislatravir</guid>
<pubDate>Tue, 21 Apr 2026 18:11:00 GMT</pubDate>
<description>RAHWAY, N.J., April 21, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) approved IDVYNSO™, a new, two-drug single-tablet regimen of 100 mg doravirine and 0.25 mg islatravir, for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of vi</description>
</item>
<item>
<title>Immuno-Oncology Drugs Market Opportunity Analysis and Forecast Report 2026-2035: Merck & Co. Remains a Dominant Force, Supported by the Commercial Success of Keytruda</title>
<link>https://6ix.com/company/merck-and-company-inc/news/immuno-oncology-drugs-market-opportunity-analysis-and-forecast-report-2026-2035-merck-and-co-remains-a-dominant-force-supported-by-the-commercial-success-of-keytruda</link>
<guid isPermaLink="true">https://6ix.com/company/merck-and-company-inc/news/immuno-oncology-drugs-market-opportunity-analysis-and-forecast-report-2026-2035-merck-and-co-remains-a-dominant-force-supported-by-the-commercial-success-of-keytruda</guid>
<pubDate>Tue, 21 Apr 2026 10:39:00 GMT</pubDate>
<description>The global immuno-oncology drugs market is expanding rapidly due to rising cancer prevalence and sustained clinical benefits. Opportunities include mRNA cancer vaccines and strategic collaborations to enhance innovation. However, high R&D costs remain a barrier, impacting pricing and access. North America leads the market. Immuno-Oncology Drugs Market Immuno-Oncology Drugs Market Dublin, April 21, 2026 (GLOBE NEWSWIRE) -- The "Immuno-Oncology Drugs Market Size, Industry Dynamics, Opportunity Ana</description>
</item>
<item>
<title>FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer</title>
<link>https://6ix.com/company/merck-and-company-inc/news/fda-grants-priority-review-for-keytrudar-pembrolizumab-and-keytruda-qlextm-pembrolizumab-and-berahyaluronidase-alfa-pmph-each-with-padcevr-enfortumab-vedotin-ejfv-for-cisplatin-eligible-patients-with-muscle-invasive-bladder-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/merck-and-company-inc/news/fda-grants-priority-review-for-keytrudar-pembrolizumab-and-keytruda-qlextm-pembrolizumab-and-berahyaluronidase-alfa-pmph-each-with-padcevr-enfortumab-vedotin-ejfv-for-cisplatin-eligible-patients-with-muscle-invasive-bladder-cancer</guid>
<pubDate>Mon, 20 Apr 2026 10:48:00 GMT</pubDate>
<description>RAHWAY, N.J., April 20, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) granted priority review for two supplemental Biologics License Applications (sBLA) for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Merck’s anti-PD-1 therapy, each in combination with Padcev® (enfortumab vedotin-ejfv), for the treatment of patients with muscle-invasive bladder cance</description>
</item>
<item>
<title>European Commission Approves Merck’s ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants During Their First RSV Season</title>
<link>https://6ix.com/company/merck-and-company-inc/news/european-commission-approves-mercks-enflonsiatm-clesrovimab-for-the-prevention-of-respiratory-syncytial-virus-rsv-lower-respiratory-tract-disease-in-infants-during-their-first-rsv-season</link>
<guid isPermaLink="true">https://6ix.com/company/merck-and-company-inc/news/european-commission-approves-mercks-enflonsiatm-clesrovimab-for-the-prevention-of-respiratory-syncytial-virus-rsv-lower-respiratory-tract-disease-in-infants-during-their-first-rsv-season</guid>
<pubDate>Fri, 17 Apr 2026 11:49:00 GMT</pubDate>
<description>RAHWAY, N.J., April 17, 2026--Merck press release announcing European Commission approval of ENFLONSIA</description>
</item>
<item>
<title>Soleo Health Appoints Joy Rowan as New Senior Vice President of Sales to Drive Strategic Growth Initiatives</title>
<link>https://6ix.com/company/merck-and-company-inc/news/soleo-health-appoints-joy-rowan-as-new-senior-vice-president-of-sales-to-drive-strategic-growth-initiatives-1</link>
<guid isPermaLink="true">https://6ix.com/company/merck-and-company-inc/news/soleo-health-appoints-joy-rowan-as-new-senior-vice-president-of-sales-to-drive-strategic-growth-initiatives-1</guid>
<pubDate>Thu, 16 Apr 2026 11:00:00 GMT</pubDate>
<description>FRISCO, Texas, April 16, 2026 (GLOBE NEWSWIRE) -- Soleo Health, an innovative leader and national provider of complex specialty pharmacy services, today announced the appointment of Joy Rowan, MS, MBA to the role of senior vice president, sales. Reporting to the chief commercial officer, Rowan will lead the Company’s field sales organization to accelerate commercial performance and deliver on its strategic growth initiatives. With over 25 years of industry experience and a proven track record of</description>
</item>
<item>
<title>New Survey Shows HPV Awareness Isn't Keeping Pace with Certain HPV-Related Cancer Trends in Canada</title>
<link>https://6ix.com/company/merck-and-company-inc/news/new-survey-shows-hpv-awareness-isnt-keeping-pace-with-certain-hpv-related-cancer-trends-in-canada</link>
<guid isPermaLink="true">https://6ix.com/company/merck-and-company-inc/news/new-survey-shows-hpv-awareness-isnt-keeping-pace-with-certain-hpv-related-cancer-trends-in-canada</guid>
<pubDate>Wed, 15 Apr 2026 11:00:00 GMT</pubDate>
<description>Merck (NYSE: MRK), known as MSD outside the United States and Canada, has released new data examining Canadians' knowledge of human papillomavirus (HPV) across age, gender, and regional groups. The survey revealed notable gaps in awareness—particularly among men and younger adults—even as rates of certain HPV‑related cancers continue to rise across the country.</description>
</item>
</channel>
</rss>